Dr. Peter E. Morris, MD
Pulmonology (Pulmonary Disease Physician)
- Medicare participating
At a glance
- Years since graduation
- 41
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 24
Licensed in Alabama since 2022, according to the Alabama Board of Medical Examiners and Medical Licensure Commission. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pulmonary Disease Physician primary
AL license 44382 (first issued 2022; active) · KY license 29391 · NC license 9901268 -
Critical Care Medicine (Internal Medicine) Physician
KY license 29391 · NC license 9901268
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- University of Alabama Hospital Birmingham, AL
Medical groups
- University of Alabama Health Services Foundation, PC (2,814 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 24
- Services billed
- 43
- Patients’ average age
- 70
| Service | Times | Patients |
|---|---|---|
| Critical care, first 30-74 minutes | 37 | 15 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Abrysvo (rsv vacc, pref a and pref b/pf) Other prescribers in Birmingham, AL | 125 |
| Shingrix (varicella-zoster ge/as01b/pf) Other prescribers in Birmingham, AL | 102 |
| Boostrix Tdap (diphth,pertuss(acell),tet vac) Other prescribers in Birmingham, AL | 40 |
| Arexvy (rsvpref3 antigen/as01e/pf) Other prescribers in Birmingham, AL | 15 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 2 companies reported 5 payments worth $5,980 in total to this clinician.
| Takeda Pharmaceuticals U.S.A., Inc. | $5,947 |
|---|---|
| Mallinckrodt Hospital Products Inc. | $32.66 |
| Consulting Fee | $5,720 |
|---|---|
| Food and Beverage | $260 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. Aug 4, 2025 | Consulting Fee | $5,720 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $16,029 in research payments for these studies, mostly to the institutions running them.
- Phase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and safety of reparixin as add-on therapy to standard of care in adult patients with Acute Respiratory …
Dompe Farmaceutici S.p.a.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.